Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDR3-targeted autologous CAR-T cells
- Development stage
- Unknown
- Lead developer
- Xiamen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CDR3-targeted autologous CAR-T cells is an autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Xiamen University. It is designed to target the complementarity-determining region 3 (CDR3) of the T-cell receptor (TCR) beta chain, which is highly variable and unique to clonal malignant T cells. By targeting the patient-specific clonal CDR3 epitope, this therapy aims to selectively eliminate malignant T cells in patients with T-cell leukemia or lymphoma while minimizing 'on-target, off-tumor' toxicity and preserving the healthy T-cell compartment. The therapy is being evaluated in a Phase 1 clinical trial in China for the treatment of relapsed or refractory T-cell leukemia, T-cell lymphoma, and T-lymphoblastic leukemia/lymphoma [ChiCTR1800014870].
- Other names
- CDR3-targeted autologous CAR-TCDR-3-targeted autologous CAR-TCDR 3-targeted autologous CAR-Tanti-CDR3 CAR-T cellsanti-CDR-3 CAR-T cellsanti-CDR 3 CAR-T cellsanti-CDR3-CarTanti-CDR-3-CarTanti-CDR 3-CarT
02
Targets
TCRβ (T-cell receptor beta chain)
Beyond the preview
Go deeper on CDR3-targeted autologous CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDR3-targeted autologous CAR-T cells.